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1 |  INTRODUCTION
The sodium channel gene SCN8A was first identified by molecu-
lar analysis of spontaneous neurological mutants in the mouse. 
Positional cloning and genome sequencing of mouse Scn8a from 
mutant lines identified two protein truncation mutations, a splice 
site mutation and a missense mutation, that were responsible for 
movement disorders ranging from tremor, ataxia, and dystonia 
to hind limb paralysis and lethality.1–3 These spontaneous mouse 
mutations resulted in partial or complete loss of function of the 
sodium channel Nav1.6 and exhibited recessive inheritance and 
the absence of spontaneous tonic/clonic seizures.
The first human epileptogenic SCN8A mutation was 
described in 2012.4 Michael Hammer at the University of 
Arizona carried out complete genome sequencing of two 
parents, an affected child, and an unaffected sibling. A de 
novo A>G mutation was identified in the affected daughter, 
resulting in the SCN8A missense mutation p.Asn1768Asp 
(N1768D).4 To assess the pathogenicity of this mutation, we 
introduced it into a Nav1.6 cDNA and carried out functional 
evaluation in transfected ND7/23 cells. We observed a large 
increase in persistent current resulting in elevated firing of 
transfected neurons.4 The causal role of the SCN8A mutation 
was confirmed in a knockin mouse model that recapitulated 
epilepsy and sudden death.5
The important role of SCN8A in epileptic encephalopathy 
was quickly confirmed in additional patients. Today, nearly 
300 individuals with SCN8A encephalopathy have been re-
ported in publications or described in databases maintained by 
family groups (eg, www.SCN8A.net). Like the first case, the 
subsequently identified mutations arose de novo in the affected 
children and resulted in missense substitutions of evolutionarily 
conserved amino acid residues that alter channel function.6 The 
patient mutations are concentrated in transmembrane segments 
of the Nav1.6 channel protein, the inactivation gate, and the cy-
toplasmic C- terminal domain (Figure 1).
Functional studies of approximately 20 patient mutations 
have been carried out by expression in transfected cells, and two 
mutations have been studied in neurons of knockin mice. None 
of the SCN8A encephalopathy mutations results in protein trun-
cation or loss of channel function. Rather, these are missense 
mutations that alter the biophysical properties of the channel, 
such as altered voltage dependence of channel activation or in-
activation, delayed channel inactivation, or increased resurgent 
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Summary
De novo mutations of the neuronal sodium channel SCN8A have been identified in 
approximately 2% of individuals with epileptic encephalopathy. These missense mu-
tations alter the biophysical properties of sodium channel Nav1.6 in ways that lead to 
neuronal hyperexcitability. We generated two mouse models carrying patient muta-
tions N1768D and R1872W to examine the effects on neuronal function in vivo. The 
conditional R1872W mutation is activated by expression of CRE recombinase, per-
mitting characterization of the effects of the mutation on different classes of neurons 
and at different points in postnatal development. Preclinical drug testing in these 
mouse models provides support for several new therapies for this devastating disor-
der. In contrast with the gain-of-function mutations in epilepsy, mutations of SCN8A 
that result in partial or complete loss of function are associated with intellectual dis-
ability and other disorders.
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or persistent current. Most mutations change more than one 
parameter, making it difficult to assign relative “severity.” The 
most common changes are a hyperpolarized shift in voltage 
dependence of activation, impaired channel inactivation, and 
elevated persistent current.6 Each of these lead to elevated neu-
ronal firing, consistent with in vivo seizures.
Approximately one- third of the patient mutations in 
SCN8A encephalopathy occur at recurrent positions, many of 
which are located in CpG dinucleotides that are sites of ele-
vated mutation rate in the human genome.7 Arginine residues 
such as 1617 and 1872 are the sites of recurrent mutations with 
dramatic effects on channel function. For example, loss of the 
positive charge at Arg1872 due to substitution of any of three 
neutral amino acids results in destabilization of the inactive 
state of the channel, resulting in elevated neuronal excitability.8
We generated two in vivo mouse models expressing patient 
mutations, the original mutation Asn1768Asp (N1768D)5 and 
the recurrent mutation Arg1872Trp (R1872W).9 Both mice 
recapitulate the basic features of encephalopathy, with spon-
taneous seizures and premature lethality. These mice enabled 
us to probe the effect of the mutations on firing patterns of 
different classes of mutations, secondary effects on expres-
sion of other genes, effects of Scn8a on cardiac function, and 
responses to new drug therapies. The effects of strain back-
ground on seizure severity have also been examined. The fea-
tures of the two mouse models are compared in Table 1.
2 |  N1768D MOUSE MODEL OF 
SCN8A  ENCEPHALOPATHY
We used targeting with a transcription activator–like effec-
tor nuclease (TALEN) endonuclease to knockin the patient 
mutation SCN8A- N1768D into exon 26 of the mouse Scn8a 
gene.10 Spontaneous seizures were observed in heterozygous 
adults beginning at 2 months of age. Mice are highly sen-
sitive to gain- of- function mutations of Scn8a, and the time 
from first observed seizure to death varies from 1 to 4 weeks 
depending on gene dosage (Figure 2).
Recordings from hippocampal neurons revealed sponta-
neous firing in subsets of CA1 and CA3 neurons (Figure 3).11 
Elevated activity was also observed in neurons from the medial 
entorhinal cortex that innervate the hippocampus.12 Although 
Nav1.6 is expressed at a much lower level in cardiac myocytes, 
this expression is sufficient to generate cardiac arrythmia in 
the N1768D mice.13,14
Secondary effects on gene expression were investigated 
by sequence analysis of transcripts from three brain regions, 
forebrain, cerebellum, and hind brain.15 Prior to seizure onset, 
we did not detect differences in transcript abundance between 
wild- type and mutant mice. Within 24 hours of the first ob-
served seizure, there was elevation of transcripts associated 
with gliosis such as glial fibrillary acidic protein as well as 
neuropeptides previously associated with seizure susceptibil-
ity such as galanin and neuropeptide Y.15 We also observed 
Key Points
• De novo gain-of-function mutations in SCN8A en-
cephalopathy alter the biophysical properties of 
sodium channel Nav1.6 and result in neuronal 
hyperexcitability
• Functional effects of pathogenic mutations in-
clude impaired channel inactivation, premature 
channel opening, and elevated persistent current
• Mouse lines expressing the SCN8A patient muta-
tions p.Asn1768Asp and p.Arg1872Trp recapitu-
late the human disorder with spontaneous seizures 
and premature lethality
• Conditional expression of p.Arg1872Trp in excit-
atory forebrain neurons causes seizures and pre-
mature lethality, but expression in inhibitory 
neurons is nonpathogenic
• Loss-of-function variants of SCN8A are less se-
vere clinically, resulting in isolated intellectual 
disability, myoclonus, or mild seizure disorders
F I G U R E  1  SCN8A mutations associated with epileptic encephalopathy. The protein structure of the four- domain sodium channel Nav1.6 is 
represented; each symbol represents a patient mutation. The positions of the two mutations studied in mouse models are indicated
S88 |   MEISLER
a significant elevation of neuropeptide W. These changes 
did not occur in mutant mice that did not develop seizures. 
We did not observe compensatory up- or downregulation of 
transcripts encoding other voltage- gated sodium channels, in-
cluding Scn1a, Scn2a, and Scn3a. The data suggest that there 
is not extensive remodeling of the brain via altered transcrip-
tion prior to seizure onset.
3 |  R1872W MOUSE MODEL OF 
SCN8A  ENCEPHALOPATHY
We used the TALEN reagent to target exon 26 of mouse 
Scn8a to generate the R1872W mutant mouse line, but in this 
case the mutation is dependent on expression of CRE recom-
binase.9 The targeting vector containing two copies of exon 
26 is shown in Figure 4A. In the absence of CRE, the mice 
express a full diploid dose of Nav1.6 that contains wild- type 
exon 26a. Expression of CRE recombinase results in deletion 
of exon 26a and initiates heterozygous expression of exon 
26b containing the R1872W mutation (Figure 4B).
We observed dramatic results after global activation 
of the mutant channel early in development by EIIA- CRE, 
with sudden onset of seizures at 14 days of age and death 
within 24 hours after the first observed seizures (Figure 5). 
Activation of R1872W specifically in excitatory neurons 
of the forebrain was sufficient to initiate seizures and death 
(Figure 5). Activation of R1872W exclusively in inhibitory 
neurons using GAD2 CRE or DLX5a CRE was not patho-
genic (Figure 5). Expression of the mutant channel in the 
adult by tamoxifen treatment of mice expressing the CAG- 
CRE- ER also resulted in 100% penetrance of spontaneous 
seizures and sudden death, demonstrating the continued sen-
sitivity of adult neurons and an apparent cell- autonomous 
effect of the mutant channel in the mature central nervous 
system (CNS).9
These results are consistent with the major role of Nav1.6 
in the initiation of action potentials at the axon initial seg-
ment of excitatory neurons, and the elevated excitability of 
neurons expressing the mutant channel. This is in striking 
contrast with the Dravet syndrome mouse, in which inhibi-
tory neurons appear to be the primary target responsible for 
seizure initiation due to reduced activity of Scn1a.16
Survival is approximately 4 weeks longer in mice express-
ing the Emx1- CRE compared with the ubiquitously expressed 
EIIA- CRE. This may be explained by the expression of the 
EIIA- CRE in many cells that do not express Emx1- CRE, in-
cluding neurons in the brainstem that regulate respiration and 
cardiac function, and cardiac myocytes that express Nav1.6 at 
a low level.13,14
4 |  PRECLINICAL DRUG TESTING 
IN SCN8A  MUTANT MICE
Existing antiepileptic drugs are inadequate for sei-
zure  control in the majority of children with epileptic 
T A B L E  1  Features of two mouse models of SCN8A encephalopathy
N1768D/+ R1872W/+
Patients Ambulatory, verbal, SUDEP at 15 y Nonambulatory, nonverbal
Channel biphysics Impaired inactivation More severely impaired inactivation
Mouse model Knockin to Scn8a of single bp substitution Knockin to Scn8a of floxed alternative exon
Onset in mouse 2- 4 months of age 2 wk of age
Duration between onset and death 1- 4 wk <1 min to 24 h
Penetrance 50%- 75% 100%
Note. The N1768D mouse was generated by transcription activator–like effector nuclease knockin of the first described patient mutation.7 The R1872W mouse carries a 
conditional allele of a recurrent human mutation that leads to lethality in early childhood.11 Onset is the age at first observed seizure. Duration is the interval between first 
observed seizure and death.
Abbreviation: SUDEP, sudden unexpected death in epilepsy.
F I G U R E  2  In vivo mouse model of the epileptic encephalopathy 
mutation SCN8A- N1768D. Knockin of the patient mutation6 results in 
seizures and death in 50% of heterozygous D/+ animals. Combination 
with a null allele (D/−) or homozygosity of the mutant allele (D/D) 
exacerbates the phenotype, demonstrating partial protection by the 
wild- type allele in heterozygous animals9
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encephalopathy. The availability of mouse mutants ex-
pressing patient mutations has made it possible to evaluate 
new therapeutic approaches. The polycyclic sodium chan-
nel modulator GS967/Prax330 acts to reduce persistent 
current.17 Nav1.6 contributes to persistent current in CNS 
neurons, as demonstrated by the reduced persistent current 
in hippocampal CA1 neurons,18 cerebellar granule cells,19 
and trigeminal mesencephalic neurons20 from Scn8a null 
mice. Administration of GS967/Prax330 in the food to 
Scn8a N1768D/+ mice rescues lethality and reduces the 
incidence of spontaneous seizures by >50%21 (Figure 6). 
The compound is also effective in mice with mutations of 
Scn1a and Scn2a,17,22 possibly an indirect consequence of 
its direct effect on wildtype Nav1.6. Phase 1 clinical trials 
of this compound are in progress.
A series of compounds with preferential effects on Nav1.6 
developed by Xenon Pharmaceuticals are in phase 1 clini-
cal trials. Antisense oligonucleotides that reduce transcript 
abundance are a potential third route to protection against 
gain- of- function mutations in SCN8A23; this approach may 
be applicable to SCN8A encephalopathy and is testable in the 
mutant mice.
F I G U R E  3  Spontaneous firing of hippocampal neurons in brain slices from N1768D mice.13 CTX, cortex; WT, wild type
F I G U R E  4  The conditional mouse mutation SCN8A- R1872W. A, Two copies of the final coding exon 26 of Scn8a were inserted into the 
endogenous gene. B, In the absence of CRE recombinase, the wild- type exon 26a is expressed. Deletion of exon 26a by CRE initiates expression of 
the mutant exon 26b.11 UTR, untranslated region; bGH, bovine growth hormone 3’UTR; R, arginine 1872; W, tryptophan 1872
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5 |  SUMMARY OF MOUSE 
MODELS
Investigation of two mouse models has clearly demonstrated 
that gain- of- function mutations of SCN8A are sufficient to gen-
erate severe seizures and a lethal phenotype. Neurons from mu-
tant mice exhibit hyperactivity, with greater severity and earlier 
lethality in the R1872W mutant. These mice have been used 
for preclinical evaluation of new drugs, accelerating progress 
to clinical trials. Analysis of the conditional R1872W mutant 
mouse demonstrated the specific role of excitatory neurons in 
SCN8A encephalopathy, in contrast to the key role of inhibi-
tory neurons in Dravet syndrome. The susceptibility of the adult 
nervous system to activation of the R1872W allele observed 
in the conditional mouse model indicates that life- long treat-
ment will be required to protect against the effects of gain- of- 
function SCN8A alleles in the CNS.
6 |  EXPANDING SPECTRUM OF 
SCN8A  DISORDERS
The addition of SCN8A into gene testing panels and the in-
crease in exome sequencing is resulting in the association of 
SCN8A with a broader spectrum of clinical conditions,24–27 
and this growth is likely to continue. Protein truncation mu-
tations and missense mutations resulting in complete loss of 
channel activity have been identified in individuals with in-
tellectual disability unaccompanied by seizures.26,28 Partial 
loss of channel activity was identified in a family with the 
SCN8A mutation that segregated with isolated myoclonus.27 
We anticipate the future discovery of many more mutations 
in patients with movement disorders like those seen in the 
spontaneous mouse Scn8a mutants, such as ataxia, dystonia, 
and essential tremor.29
ACKNOWLEDGMENTS
Our work on SCN8A has been supported by NIH R01 
NS034509 and by the Dravet Syndrome Foundation, the 
Wishes for Elliott Foundation, and the Cute Syndrome 
Foundation. I thank Dr Jacy Wagnon for helpful discussions.
DISCLOSURE
The author has no conflict of interest to disclose. I confirm 
that I have read the Journal's position on issues involved in 
ethical publication and affirm that this report is consistent 
with those guidelines.
REFERENCES
 1. Burgess DL, Kohrman DC, Galt J, et al. Mutation of a new sodium 
channel gene, SCN8A, in the mouse mutant ‘motor endplate dis-
ease’. Nat Genet. 1995;10(4):461–5.
 2. Kohrman DC, Harris JB, Meisler MH. Mutation detection in the 
med and medJ alleles of the sodium channel SCN8A. Unusual 
splicing due to a minor class AT- AC intron. J Biol Chem. 
1996;271:17576–81.
 3. Kohrman DC, Smith MR, Goldin AL, Harris J, Meisler MH. A 
missense mutation in the sodium channel Scn8a is responsi-
ble for cerebellar ataxia in the mouse mutant jolting. J Neurosci. 
1996;16:5993–9.
F I G U R E  5  Predominant role of excitatory neurons in 
SCN8A encephalopathy in the conditional R1872W mouse. Global 
preimplantation activation of the mutant allele by EIIA- CRE results in 
seizure onset at 2 weeks of age followed rapidly by lethality. Activation 
of the mutant allele in excitatory forebrain neurons by Emx1 CRE 
also results in 100% penetrance of seizures and death, approximately 
4 weeks later than the EIIA- CRE. In contrast, activation by the GAD2 
CRE in inhibitory neurons had no detectable pathogenicity11
F I G U R E  6  Rescue of Scn8a- N1768D mice by GS967/
Prax330. The polycyclic drug GS967/Prax33018 was incorporated 
into pelleted food and fed to the heterozygous mutant mice from 
the age of 1.5 months (before seizure onset) to 6 months. The mice 
were protected against seizures and neurotoxicity until removal of 
the drug.19 P < .0001 (log- rank). Disease penetrance was higher than 
in Figure 2; this represents experimental variability within the same 
mouse line
   | S91MEISLER
 4. Veeramah KR, O'Brien JE, Meisler MH, et al. De novo pathogenic 
SCN8A mutation identified by whole- genome sequencing of a 
family quartet affected by infantile epileptic encephalopathy and 
SUDEP. Am J Hum Genet. 2012;90:502–10.
 5. Wagnon JL, Korn MJ, Parent R, et al. Convulsive seizures and 
SUDEP in a mouse model of SCN8A epileptic encephalopathy. 
Hum Mol Genet. 2015;24:506–15.
 6. Meisler MH, Helman G, Hammer MF, et al. SCN8A encephalopa-
thy: research progress and prospects. Epilepsia. 2016;57:1027–35.
 7. Wagnon JL, Meisler MH. Recurrent and non- recurrent mutations 
of SCN8A in epileptic encephalopathy. Front Neurol. 2015;6:104.
 8. Wagnon JL, Barker BS, Hounshell JA, et al. Pathogenic mecha-
nism of recurrent mutations of SCN8A in epileptic encephalopa-
thy. Ann Clin Transl Neurol. 2016;3:114–23.
 9. Bunton-Stasyshyn RKA, Wagnon JL, Wengert ER, et al. Prominent 
role of forebrain excitatory neurons in SCN8A encephalopathy. 
Brain. 2019;142(2):362–75.
 10. Jones JM, Meisler MH. Modeling human epilepsy by TALEN tar-
geting of mouse sodium channel SCN8A. Genesis. 2014;52:141–8.
 11. Lopez-Santiago LF, Yuan Y, Wagnon JL, et al. Neuronal hyperex-
citability in a mouse model of SCN8A encephalopathy. Proc Natl 
Acad Sci U S A. 2017;114:2383–8.
 12. Ottolini M, Barker BS, Gaykema RP, Meisler MH, Patel MK. 
Aberrant sodium channel currents and hyperexcitability of medial 
entorhinal cortex neurons in a mouse model of SCN8A encepha-
lopathy. J Neurosci. 2017;37:7643–55.
 13. Noujaim SF, Kaur K, Milstein M, et al. A null mutation of the neu-
ronal sodium channel NaV1.6 disrupts action potential propagation 
and excitation- contraction coupling in the mouse heart. FASEB J. 
2012;26:63–72.
 14. Frasier CR, Wagnon JL, Bao Y, et al. Cardiac arrhythmia in a 
mouse model of SCN8A epileptic encephalopathy. Proc Natl Acad 
Sci U S A. 2016;113:12838–43.
 15. Sprissler RS, Wagnon JL, Bunton-Stasyshyn RK, Meisler MH, 
Hammer MF. Altered gene expression profile in a mouse model 
of SCN8A epilepsy reveals reactive astrocytosis in response to sei-
zures. Exp Neurol. 2016;288:134–41.
 16. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium 
current in GABAergic interneurons in a mouse model of severe 
myoclonic epilepsy in infancy. Nat Neurosci. 2006;9:1142–9.
 17. Anderson LL, Thompson CH, Hawkins NA, et al. Antiepileptic 
activity of preferential inhibitors of persistent sodium current. 
Epilepsia. 2014;55:1274–83.
 18. Royeck M, Horstmann MT, Remy S, Reitze M, Yaari Y, 
Beck H. Role of axonal NaV1.6 sodium channels in action 
potential initiation of CA1 pyramidal neurons. J Neurophysiol. 
2008;100:2361–80.
 19. Osorio N, Cathala L, Meisler MH, Crest M, Magistretti J, 
Delmas P. Persistent Nav1.6 current at axon initial segments tunes 
spike timing of cerebellar granule cells. J Physiol. 2010;588(Pt 4): 
651–70.
 20. Enomoto A, Han JM, Hsiao CF, Chandler SH. Sodium currents 
in mesencephalic trigeminal neurons from Nav1.6 null mice. J 
Neurophysiol. 2007;98:710–9.
 21. Baker EM, Thompson CH, Hawkins NA, et al. The novel sodium 
channel modulator GS- 458967 (GS967) is an effective treat-
ment in a mouse model of SCN8A encephalopathy. Epilepsia. 
2018;59:1166–76.
 22. Anderson LL, Hawkins NA, Thompson CH, Kearney JA, George 
AL. Unexpected efficacy of a novel sodium channel modulator in 
Dravet syndrome. Sci Rep. 2017;7:1682.
 23. Roovers J, De Jonghe P, Weckhuysen S. The therapeutic potential 
of RNA regulation in neurological disorders. Expert Opin Ther 
Targets. 2018;22:1017–28.
 24. Larsen J, Carvill GL, Gardella E, et al. The phenotypic spectrum of 
SCN8A encephalopathy. Neurology. 2015;84:480–9.
 25. Gardella E, Becker F, Moller RS, et al. Benign infantile seizures 
and paroxysmal dyskinesia caused by an SCN8A mutation. Ann 
Neurol. 2016;79:428–36.
 26. Wagnon JL, Barker BS, Ottolini M, et al. Loss- of- function muta-
tions of SCN8A in intellectual disability without seizures. Neurol 
Genet. 2017;3:e170.
 27. Wagnon JL, Mencacci NE, Barker BS, et al. Partial loss- of- function 
of sodium channel SCN8A in familial isolated myoclonus. Hum 
Mutat. 2018;39:965–9.
 28. Trudeau MM, Dalton JC, Day JW, Ranum LP, Meisler MH. 
Heterozygosity for a protein truncation mutation of sodium chan-
nel SCN8A in a patient with cerebellar atrophy, ataxia and mental 
retardation. J Med Genet. 2006;43:527–30.
 29. Sharkey LM, Jones JM, Hedera P, Meisler MH. Evaluation of 
SCN8A as a candidate gene for autosomal dominant essential 
tremor. Parkinsonism Relat Disord. 2009;15:321–3.
How to cite this article: Meisler M. SCN8A 
encephalopathy: Mechanisms and models. Epilepsia. 
2019;60(S3):S86–S91. https://doi.org/10.1111/
epi.14703
